Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Niagen Bioscience, Inc. (NAGE) until August 12, 2022. Niagen Bioscience, Inc. reported in an 8-K filed August 10, 2022 that Kevin Farr was terminated as director, effective August 12, 2022. Niagen Bioscience, Inc. reported in an 8-K filed August 10, 2022 that Kevin Farr was terminated as Chief Financial Officer, effective August 12, 2022. The proxy statement of Niagen Bioscience, Inc. reports total compensation of $839,537 for Kevin Farr in fiscal 2022, including a base salary of $197,975. Disclosed compensation is on record for 4 fiscal years. Kevin Farr has spoken on 9 earnings calls across 1 company, most recently for Niagen Bioscience, Inc. on May 12, 2022. The companies whose calls Kevin Farr spoke on are classified in the Consumer Defensive sector.
“On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.”
“On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.”
“ChromaDex delivered a solid quarter with total net sales of $17.3 million, up 18% year-over-year, and a gross margin of 61%. With a significant litigation expense behind us, we are prioritizing investments in marketing, including our new Tru Niagen TV campaign that began airing in late March.”
“ChromaDex delivered on or exceeded our latest full year 2021 financial outlook to investors across all metrics. For the year, we delivered total net sales of $67.4 million, a 14% year-over-year increase with strong growth in Tru Niagen of 20%, including 21% growth in e-commerce.”
“ChromaDex delivered a solid quarter with total net sales of $17.3 million, up 22% year-over-year, and a gross margin of 61.1%. The underlying business as measured by adjusted EBITDA excluding legal expense, a non-GAAP metric, posted a loss of only $621,000 in the third quarter.”
“ChromaDex delivered a strong quarter, with total net sales of $17.7 million, up 16% year-over-year, or about 30%, excluding the $1.6 million Horizon Ventures purchase last year and up 21% sequentially.”
“ChromaDex delivered a solid first quarter and continues to demonstrate financial discipline while making important investments to protect our intellectual property.”
Proxy statement
Start not stated–2020-04-21
Last confirmed by a filing; no departure on record
Start not stated–2022-08-12
Packaged Foods · Consumer Defensive
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Niagen Bioscience, Inc. (NAGE) | Former Chief Financial Officer | $197,975 | $839,537 |
| 2021 | Niagen Bioscience, Inc. (NAGE) | Former Chief Financial Officer | $309,000 | $626,429 |
| 2020 | Niagen Bioscience, Inc. (NAGE) | Former Chief Financial Officer | $320,884 | $688,816 |
| 2019 | Niagen Bioscience, Inc. (NAGE) | Chief Financial Officer | $306,577 | $621,503 |
